Verici Dx PLC Ordinary Shares VRCI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 7.25
- Day Range
- GBX 7.00–8.00
- 52-Week Range
- GBX 5.50–19.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 1.82 Bil
- Volume/Avg
- 84,966 / 378,932
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 778.54
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.vericidx.com
Valuation
|
Metric
|
VRCI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.69 |
Price/Sales | 778.54 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VRCI
|
|---|---|
Quick Ratio | 2.45 |
Current Ratio | 2.58 |
Interest Coverage | −568.05 |
Quick Ratio
VRCI
Profitability
|
Metric
|
VRCI
|
|---|---|
Return on Assets (Normalized) | −76.42% |
Return on Equity (Normalized) | −135.83% |
Return on Invested Capital (Normalized) | −90.00% |
Return on Assets
VRCI
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Fsmrfwqsvr | Kyx | $209.3 Bil | |
DHR
| Danaher Corp | Sgmwdbpbjq | Msskrpz | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Thztcxzb | Swtbcrm | $42.8 Bil | |
IDXX
| IDEXX Laboratories Inc | Bnwywylbht | Pzrzcvj | $41.5 Bil | |
A
| Agilent Technologies Inc | Rnxbfxzqn | Hrj | $40.9 Bil | |
MTD
| Mettler-Toledo International Inc | Ydmkfyqcz | Hbxrv | $26.8 Bil | |
ICLR
| Icon PLC | Sbrrhtstq | Xxyztz | $25.1 Bil | |
ILMN
| Illumina Inc | Qkdntrxzr | Ytnfh | $19.5 Bil | |
WAT
| Waters Corp | Ygghjmwjvr | Zhzf | $18.5 Bil | |
LH
| Laboratory Corp of America Holdings | Nbblbvtlg | Bqjfgn | $16.7 Bil |